Haemophilas influenzae type b (Hib) capsular polysaccharide (PRP) was selectively hydrolyzed to reducing oligosaccharides, and the fraction containing 3-10 ribosylribitolphosphate repeating units (VS) 
Introduction
Serum antibodies (Ab)' to the capsular polysaccharide can protect against invasion by Haemophilus influenzae type b (Hib). Vaccination with the capsular polysaccharide of Hib (PRP) appears to induce a response adequate for protection above the age of 18 mo (1). Since the maximal age incidence of Hib meningitis is -9 mo (1), several laboratories have tried to increase the immunogenicity of PRP 1. Abbreviations used in this paper: Ab, antibody; AU, antitoxinneutralizing units; BC, bactericidal; Dcr, cross-reacting material 197 (CRM197); DTd, diphtheria toxoid; DTx, diphtheria toxin; ELISA, enzyme-linked immunosorbent assay; Hib, Haemophilus influenzae type b; PAGE, polyacrylamide gel electrophoresis; Pi, inorganic phosphate; PRP, Haemophilus influenzae type b capsular polysaccharide; Td, adult-type tetanus-diphtheria toxoid vaccine; USFDA, U. S. Food and Drug Administration. approach to the problem has used an old principle, the covalent coupling of polysaccharides or related oligosaccharides to a carrier protein (2). The former (coupling of intact PRP) is being examined by Chu and colleagues (3) . To examine the latter possibility (4) we conjugated oligosaccharides of PRP to cross-reacting material 197 (CRM197) (Dcr) (5), a nontoxic derivative of diphtheria toxin (DTx); in weanling rabbits the conjugates induced high titers of anti-PRP Ab in an anamnestic pattern, and the Ab were bactericidal (BC) to Hib in vitro (4) .
Here, such conjugates were studied in humans. In addition to Dcr, native DTx and formalinized diphtheria toxoid (DTd) were tried as carriers. Adults were injected to examine for adverse reactions, for immunogenicity of the Hib and diphtheria components, and for the protective potential of the Ab elicited. Infants 19-23 and 12-16 mo of age were tested, and secondary injections were given to look for an anamnestic response.
Methods
Purified DTx (lot 1) and DTd (lot Dcp 27) were obtained from W. Latham of the Massachusetts Department of Public Health Biolabs, Jamaica Plain, MA. Dcr was isolated by (NH4)2SO4 fractionation and chromatography as described (5) from Corynebacterium diphtheriae C7 (B197) furnished by J. R. Murphy, Boston University. Bovine serum albumin (BSA) was Cohn Fraction V from Sigma Chemical Co., St. Louis, MO. Protein was assayed by the method of Lowry et al. (6) with BSA as the standard. Electrophoresis in polyacrylamide gels containing sodium dodecyl sulfate (SDS-PAGE) was as described by Laemmli (7) (Fig. 1) . The DTx and Dcr preparations, as expected, appeared as three discrete bands: the 62,000-mol-wt native molecule and the A and B fragments (24,000 and 38,000 mol wt, respectively) produced by reduction of "nicked" molecules (5) . The DTd preparation appeared mainly as a diffuse band with a molecular weight of 60-70,000, with a small proportion of higher molecular weight material (presumably protein cross-linked by formalin [8] ). PRP in sodium salt form was isolated from Hib strain Eag as described (9) . PRP is a linear polymer of the repeating structure (3-fl-D-ribose ribitol-5-phosphate-). Cleavage of the 1-1 bond produces one reducing ribosyl and one nonreducing ribitol terminus; the other two possible cleavages produce a phosphate monoester. For oligosaccharides with a high proportion of reducing termini, 120 mg PRP in 12 ml water at 0C was made 0.1 N with HCl, heated 4 min at 1000C, cooled, neutralized with triethylamine, and applied to and eluted from a 1.5 X 98-cm column of Bio-Gel P-10 (Bio-Rad Laboratories, Richmond, CA) equilibrated with sterile 0.01 M triethyl ammonium acetate. The fractions with elution coefficients of 0.4-0.9 were combined, designated "VS," and characterized as follows: total ribose content was assayed by the orcinol reaction (10) with D-ribose as standard. Content of ribose at reducing termini was estimated by the Park-Johnson assay for reducing sugars (10) Infant subjects were healthy and had had no prior immunization with Hib vaccine nor history of serious adverse reaction to vaccines. The first group began the study at age 19-23 mo and at least one month after routine vaccination with diphtheria-tetanus-pertussis vaccine. They were bled, given a 25-gg subcutaneous injection of Dcr-VS, DTd-VS, or PRP vaccine, observed at least 20 min, and released to their parents for observation and recording of possible local and systemic adverse reactions. About 1 mo later this process was repeated with the same vaccine. About I mo and -4 mo later they were again bled. A second group began the study at age 12-16 mo; thus the secondary Hib vaccination came at least I mo before the scheduled routine diphtheria-tetanus-pertussis booster at age 18 mo. Subjects received either Dcr-VS or DTd-VS as described for the 19-23-mo-old group; control data were taken from a previous study in a similar population (17) .
Total Ab to PRP was measured in a Farr-type radioassay using [3HJPRP (18) of storage at 4°C a trace of toxicity became detectable. Storage at 37°C accelerated the retoxification, which, however, never increased above the 1% observed before formalin. In weanling rabbits the conjugates strongly elicited Ab reactive with native PRP (Fig. 3, left) and Ab reactive with DTd (Fig. 3, center) . After a sequence of three injections, these two Ab activities were detectable in sera diluted < 1:1,000. However, the binding of ['4C]ribitolyl-BSA (a model ligand for the linkage) was not detectable either before or after immunization, even in undiluted samples of these sera (Fig.  3, right) .
Studies in human adults. At the site of intradermal injection, one recipient of DTd-VS displayed an immediate dermal flare reaction of 20 mm diameter (but no other symptoms) and was not further immunized. The other 18 had no apparent reaction within 20 min and were given a 5-jug or 25-jig s.c. injection (three subjects per dose level for each of the three vaccines). None had any local reaction apparent within 20 min. Overall, in the following 3 d (Table II) , one subject had moderate local inflammation and mild systemic symptoms, seven subjects had mild local inflammation only, and the remaining 10 subjects had no discernible reaction. Generally the inflammation at the subcutaneous site was maximal on day 2 postinjection, the reactions were painless, and the erythema and induration did not exceed 35 mm in diameter. The diameter of induration was not significantly different among the three conjugate vaccines or between the 5-jug and 25-jig s.c. doses, and was unrelated to the subject's preimmunization anti-PRP Ab level but positively correlated with preimmunization IgG Ab to DTd (r = 0.58, P < 0.01). The one subject with systemic symptoms had had among the highest preimmunization antiDTd titers and had the most severe local inflammation, 70 mm induration at the subcutaneous site.
Increases in total anti-PRP Ab measured by radioassay at 2 wk postimmunization occurred in four of six, six of six, and five of six subjects after DTx-VS, Dcr-VS, and DTd-VS, respectively (Table III) . There was considerable variation in the Ab levels before immunization, and thus the postimmunization differences among the three vaccines or between the 5-jig and 25-jig doses were not considered meaningful. ( (Table III) . In 14 of the 15 responders to conjugate vaccines, the Ab levels fell between 2 wk and 4 wk postimmunization (mean ratio 0.76), while one subject had a ratio of 1.1 (data not tabulated). Serum BC activity against Hib increased with a frequency similar to that in radioantigen binding, and the increases in the two assays were positively correlated (for increase in micrograms of anti-PRP per milliliter vs. log2 of increase in BC titer, r = 0.66, P < 0.01). The geometric mean of the ratio of postimmunization BC titer to micrograms of Ab per milliliter was 1.1 (±SD 0.39-2.9) in comparison with 1.0 for the USFDA standard human anti-PRP serum (SK). From the six subjects in which the pre/post ratio in anti-PRP Ab was 39, a pool of pre-and a pool of postimmunization sera were compared in passive protection of infant rats challenged intraperitoneally with Hib. The 50% protective titer against bacteremia was increased about eightfold by the immunization.
The IgG anti-DTd Ab increased in all subjects (Table III) . The increases did not differ significantly among the three vaccines or between the two doses. Both pre-and postimmunization Ab were predominantly of the IgG class; IgM and IgA Ab were lower and increased less consistently (not tabulated). The geometric mean of all 18 subjects postimmunization was equivalent to 0.57 antitoxin-neutralizing units (AU)/ml (where the minimal protective value is estimated as 0.01 AU/ml). For comparison, the values of a control group of 10 subjects vaccinated with conventional Td vaccine increased to a geometric mean of 0.51 AU/ml. Separately for the three conjugates, pools were made of the six pre-and the six 2-wk postimmunization sera, and these were assayed for in vitro neutralization of DTx in the rabbit skin assay. In each group the neutralizing Ab value increased approximately fivefold. There was no correlation between the anti-PRP and anti-DTd Ab responses to the conjugates, whether analyzed by relative after DTd-VS, and in 13 of 16 after immunization with 25 ,ug of PRP (an optimal dose). At 1 mo after the secondary injection of PRP only 3 of the 16 infants had increases, and the geometric mean (Fig. 4) did not rise. In contrast, after either of the conjugates there were postsecondary increases in eight of eight infants. The geometric mean after DTd-VS (3.1 tsg/tnl) significantly exceeded that after PRP (0.50 ,ug/ml), and that after Dcr-VS (15 gg/ml) exceeded both the others. By 5 mo after the secondary the means of all three groups had declined; the falloff after Dcr-VS was faster, such that Dcr-VS and DTd-VS no longer differed significantly but both exceeded PRP (Fig. 4) .
Before immunization none of the infants had detectable BC activity (<50% killing at 1:2 dilution), and the anti-PRP Ab as detected in an Ig class-specific ELISA was largely IgM (Fig. 5) . After the primary injection with any of the vaccines small increases in BC activity were found in just under half the subjects, and rises in the class-specific ELISA were mainly in IgM with a few small rises in IgG and IgA (not shown). At 1 mo after the secondary, BC activity was found in 6 of 16 infants after PRP, in 6 of 8 after DTd-VS, and in 8 of 8 after Dcr-VS; the mean log2 for 50% killing increased to 0.3, 0.8, and 3.1, respectively (Fig. 5) . For DTd-VS and Dcr-VS combined, the geometric mean ratio of BC titer to micrograms of anti-PRP Ab per milliliter was 0.64 (±SD 0.27-1.5). There was little change in Ig class distribution after the secondary Groups of 8 subjects were injected subcutaneously with 25 gg of conjugate vaccine and a group of 16 subjects with 25 jig of PRP vaccine just after the serum sample at 0 mo and again after sample at I mo. Ab concentrations were estimated by radioantigen binding.
The vertical bars show a 95% confidence interval for the geometric means. (Fig. 5 ).
Generally the subjects had high levels of Ab to DTd before immunization. All had rises after both the primary and secondary injections. The geometric means preimmunization and 1 mo postsecondary were 0.75 and 3.1 AU/ml, respectively, with Dcr-VS, and 0.64 and 3.9 AU/ml with DTd-VS.
Studies in infants 12-16 mo of age. Groups of four each were given Dcr-VS or DTd-VS in the same schedule as in the older infants. There were no observed local or systemic adverse reactions (Table II) . Increases in total anti-PRP Ab (Table IV) measured 1 mo after the primary were found in four of four after Dcr-VS, two of four after DTd-VS, and three of eight in the (noncohort) control group that received PRP; the levels in the Dcr-VS group were significantly higher than in the other two groups by the rank sum test (P < 0.05). At 1 mo after the secondary there were no further increases in the PRP group, small additional rises in the two primary responders in the DTd-VS group, and large increases in four of the four in the Dcr-VS group, which had a geometric mean (4.4 l.g/ml) -50-fold higher than the other two (P < 0.05 by rank sum test or (23) . Protein-coupled capsular antigens have been described as potential immunogens against Neisseria meningitidis (24, 25) and Streptococcus pneumoniae (3, 26) as well as Hib (3, 27, 28) , and enhanced Ab responses have been found in experimental animals. Because of species differences in antisaccharide responses (10) and because the maturation of immunocompetence in laboratory animal species proceeds on a schedule different from humans (29) , the optimal properties of such immunogens may need to be defined in immunogenicity studies in human infants. The methodology described in reference 27 has been used to make protein-coupled (polymeric) PRP that has an increased immunogenicity in human adults (28) and infants (30, 31) . Our approach to coupled capsular immunogens included depolymerizing the PRP and using a simple coupling chemistry. Highly polymerized identical epitopes are believed to account for the T lymphocyte-independent character of polysaccharide antigens (23) , thus the presentation of oligosaccharides on the carrier protein might make the conjugate more subject to T lymphocyte helper effects. Empirically, it was recently found that protein conjugates made with low molecular weight dextrans gave higher secondary responses in mice than conjugates made with macromolecular dextran (32). Our coupling was done without linker compounds, whose pharmacologic properties are difficult to evaluate, and employed reductive amination, which forms a simple amino linkage (12) unlike the linkages present in natural glycoproteins (33) . It As a potential carrier, DTd has a record of safe human usage and is readily available; we also examined DTx and Dcr, in which more amino groups are accessible for coupling but which have the drawbacks of potential toxicity and limited supply, respectively (4) . Experience with tetanus toxin (35) suggested that the coupling reaction would reduce the toxicity of DTx, as was found. Formalinization of the conjugates after coupling (done for stabilization of the diphtheria component [5] ) also reduced the residual 1% toxicity of DTx-VS by >100-fold. However, there was a slight retoxification upon storage at 4VC and a faster one at 370C. Reversibility of the detoxification of purified DTx by formaldehyde is commonly observed (8) . Thus, in the absence of compelling advantages of beginning with native toxin, making conjugates with the inherently nontoxic Dcr or stably detoxified DTd are preferable.
8 of the 18 immunized adults had delayed local inflammation, the degree of which was correlated with preimmunization IgG Ab to the diphtheria component. Potentially, the Ab could be a mediator of the reaction (Arthus) or merely an indicator of sensitization (with the reaction being cell-mediated). Since hypersensitivity is common after reimmunization of adults with diphtheria and tetanus toxoids (36), reactions after the conjugates were expected. Hypersensitivity reactions to toxoids is less of a problem in infants, and the same appeared to be true of these conjugates.
The adults consistently made an anti-PRP Ab response to the conjugates, and these Ab were similar to those raised by PRP in protective potential. Secondary injections to examine for secondary responses were not done due to the potential for hypersensitivity.
Infants 18-23 mo of age were appropriate for a controlled comparison because the response to PRP vaccine was immature but readily measurable and marginally protective, thus either a superior or an inferior immunogenicity of the conjugates could be detected. The telling results were the responses to secondary immunizations and the Ig class distributions. As in previous studies (17) , the second injection of PRP generally failed to boost the Ab level, while with both tested conjugates there were exponentially increased levels 1 mo after the secondary. Multiple sera were not obtained before the secondary to establish that the primary response had plateaued; however, since the adult Ab levels at 2 wk exceeded those at 4 wk postimmunization, the rises in infants after the secondary probably represents an anamnestic response rather than a continued response to the primary. As expected (1), the response to PRP in most of the infants was restricted to the IgM class, with but a few rises also in IgG. In contrast, the secondary responses to the conjugates showed an increased participation of IgG, characteristic of more mature responses to PRP (1) .
It is now known that immunization with PRP below 18 mo of age is unlikely to be protective (1) . Thus in the 12-16 mo age range, data previously obtained (17) were used as a control rather than a PRP-vaccinated cohort. DTd-VS was only weakly immunogenic, while Dcr-VS showed an increased primary and a sharply enhanced secondary response with an IgG component. The total Ab after Dcr-VS also was high in relation to levels estimated to be protective (37) . The ratios of BC titer to anti-PRP Ab level further indicate that the Ab induced in infants by the conjugated oligosaccharide have a protective potential against encapsulated Hib.
Conjugate Dcr-VS elicited significantly higher Ab levels in both groups of infants than DTd-VS. The 5-mo falloff after Dcr-VS was also faster. The basis is uncertain, but we speculate that both observations might result from the aggregated state of Dcr-VS, which could enhance both immunologic processing as well as elimination of the antigen.
It might eventually be useful to substitute a conjugate for ordinary DTd in routine immunization. Thus it was welcome that the immunized subjects had a rise in Ab to DTd and (in the tested adults) a rise in DTx neutralizing activity.
